Letters in Drug Design & Discovery

G. Perry
University of Texas
San Antonio, TX
USA
Email: lddd@benthamscience.org

Back

Computer-Aided Drug Design for Cancer-Causing H-Ras p21 Mutant Protein

Author(s): Mannu Jayakanthan, Gulshan Wadhwa, Thangavel Madhan Mohan, Loganathan Arul, Ponnusamy Balasubramanian, Durai Sundar.

Abstract:

GTP-bound mutant form H-Ras (Harvey-Ras) proteins are found in 30% of human tumors. Activation of H-Ras is due to point mutation at positions 12, 13, 59 and/or 61 codon. Mutant form of H-Ras proteins is continuously involved in signal transduction for cell growth and proliferation through interaction of downstream-regulated protein Raf. In this paper, we have reported the virtual screening of lead compounds for H-Ras P21 mutant protein from ChemBank and DrugBank databases using LigandFit and DrugBank-BLAST. The analysis resulted in 13 hits which were docked and scored to identify structurally active leads that make similar interaction to those of bound complex of H-Ras P21 mutant- Raf. This approach produced two different leads, 3-Aminopropanesulphonic acid (docked energy -3.014 kcal/mol) and Hydroxyurea (docked energy -0.009 kcal/mol) with finest Lipinskis rule-of-five. Their docked energy scores were better than the complex structure of H-Ras P21 mutant protein bound with Raf (1.18 kcal/mol). All the leads were docked into effector region forming interaction with ILE36, GLU37, ASP38 and SER39.

Keywords: Molecular docking, H-Ras, Rational drug design, Ras-Raf Interaction, LigandFit, Binding affinity

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 6
ISSUE: 1
Year: 2009
Page: [14 - 20]
Pages: 7
DOI: 10.2174/157018009787158526